Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 8.01
Syndax disclosed an R&D event on July 14, 2026, highlighting late-stage programs and unveiling two new pipeline assets: SNDX-4321 (a novel allosteric EGFR inhibitor for NSCLC with IND submission expected by end of 2026 and Phase 1 initiation in 2027) and SNDX-62122 (a next-generation menin inhibitor for myelofibrosis with IND submission and Phase 1 expected in 2027). This represents a material strategic expansion of the company's pipeline with new differentiated assets supported by preclinical data, which would affect a reasonable investor's assessment of the company's R&D capabilities and growth opportunities. The event is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 2.01
flyExclusive completed a material acquisition of Jet.AI's aviation assets on July 14, 2026, pursuant to Amendment No. 5 to the Amended and Restated Merger Agreement executed on July 13, 2026. The transaction involved a merger of Merger Sub into SpinCo (a Jet.AI entity), with SpinCo becoming a wholly owned subsidiary of flyExclusive, and consideration consisting of 7,096,117 shares of Company Common Stock, aircraft, customer relationships, future aircraft delivery positions, SPCX marketable securities, and cash.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 2.01
On July 14, 2026, Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation, with stockholders receiving $39.00 per share in cash plus contingent value rights tied to pending litigation proceeds. The transaction constitutes a material change of control and merger completion, with the company's stock delisted from Nasdaq and registration to be terminated via Form 15.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Following the completion of the Ligand Pharmaceuticals acquisition, XOMA Royalty notified Nasdaq to halt trading and delist its shares effective July 14, 2026, and intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-14
Item 5.07
At a Special Meeting of Stockholders held on July 13, 2026, stockholders approved three proposals: the Merger Agreement (15,924,106 votes for), the Holding Company Reorganization (15,924,259 votes for), and the Compensation Proposal (15,745,257 votes for), all related to the Ligand Pharmaceuticals acquisition.
View raw filing on EDGAR →
8-K
Governance Other
confidence 95%
filed 2026-07-14
Item 5.02
Effective upon the completion of the Ligand Pharmaceuticals acquisition, all prior directors of XOMA Royalty resigned and were replaced by Merger Sub's directors and officers, reflecting the change of control and board transition resulting from the merger closing.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-14
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A details multiple debt issuances with trade dates of 7/8/2026 through 7/10/2026, including variable-rate floaters totaling $1.46 billion and fixed-rate bonds totaling approximately $38 million. The registrant explicitly states that "consolidated obligations issuance is material to the FHLBank," confirming the materiality of this debt creation event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for $39.00 per share in cash (approximately $739 million equity value) plus contingent value rights. The transaction doubles Ligand's royalty portfolio from approximately 100 to over 200 assets, adds seven commercial products and 14 late-stage development programs, and is expected to be accretive to earnings per share by $0.50 and $1.50 in 2026 and 2027 respectively.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Navigator Holdings announced the signing of definitive agreements to sell eight gas carriers and its shareholding in the Unigas Joint Venture for approximately $183 million to existing Unigas partners. This is a material disposition transaction involving the sale of significant fleet assets and a joint venture stake, expected to close by Q4 2026. The transaction represents a substantial capital event affecting the company's fleet composition and financial position.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-07-14
Item 7.01
Management made a material misstatement of full-year Adjusted EBITDA guidance during a July 13 conference call, citing $330-$345 million instead of the correct $335-$350 million stated in the prior press release. This disclosure corrects the error and clarifies that guidance remains unchanged. While the event involves guidance correction, it does not fit neatly into earnings_release (no new results disclosed) or other specific categories; it is a material disclosure of a management error affecting investor reliance on publicly stated guidance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-07-14
Item 1.01
Fidelity Private Credit Co LLC entered into a Fifth Amendment to its Loan and Security Agreement, materially restructuring its credit facility by converting $200 million in Tranche B commitments from term loan to revolving loan commitments and reducing Tranche A commitments from $800 million to $500 million. The amendment contemplates Fund II's assumption of all obligations upon merger consummation, constituting a material modification and refinancing of the Fund's direct financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 45%
filed 2026-07-14
Item 1.01
The filing discloses entry into registration rights agreements following conversion of $15 million in Senior Secured Convertible Promissory Notes into 1.54 million common shares. While the registration rights agreements themselves are ancillary to the underlying debt conversion, the Item 1.01 disclosure centers on the creation of registration obligations tied to a material debt instrument. However, the debt was issued in January and February 2025 and converted in March 2026; the July 2026 filing documents only the registration rights agreement entered into post-conversion, which is a secondary contractual arrangement rather than a primary debt issuance or material M&A event. This is a borderline case between debt_issuance (the original notes, now converted) and financial_other (the registration rights agreement itself).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 93%
filed 2026-07-14
Item 1.01
Wabash National entered into a Fifth Amendment to its Credit Agreement permitting up to $150 million in additional indebtedness and commenced a private offering of $100 million aggregate principal amount of convertible senior unsecured notes due 2032 (with an option for an additional $15 million), representing a material creation of new direct financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-14
Item 2.02
Phoenix Education Partners issued a press release on July 14, 2026, reporting financial results for the three and nine months ended May 31, 2026 and 2025, disclosing net revenue of $271.8 million for Q3 2026, net income of $39.2 million ($1.01 diluted EPS), and providing fiscal year 2026 guidance. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and operational trends.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
Zachary F. Sadek was appointed to the Board of Directors effective July 13, 2026, pursuant to a Cooperation Agreement with PCP Managers II, L.P. (Parthenon Capital), one of the Company's largest stockholders, expanding the board from six to seven members.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-14
Item 1.01
Kestra Medical Technologies entered into a $200 million senior secured term loan facility on July 10, 2026, with $75 million funded immediately (Tranche A), replacing its prior loan agreement. The new facility has customary covenants, security interests in substantially all assets, and a five-year maturity, representing a material refinancing that fortified the company's balance sheet.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-14
Item 2.02
Kestra Medical Technologies disclosed financial results for the fourth quarter and fiscal year ended April 30, 2026, reporting revenue of $95.1 million (59% year-over-year growth), gross margin expansion to 51.4%, and fiscal 2027 revenue guidance of $137 million. The disclosure includes consolidated financial statements and detailed financial highlights.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-14
Item 2.02
Equity Bancshares issued a press release on July 14, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $26.4 million ($1.27 per diluted share) and core EPS of $1.41, along with an investor call presentation to discuss the quarterly results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
Paramount Gold Nevada Corp. filed a technical report summary for its Grassy Mountain Gold Project prepared in accordance with SEC Regulation S-K subpart 1300. This is a comprehensive feasibility study covering mineral resources, reserves, mining methods, processing, infrastructure, environmental permitting, and economic analysis. While not fitting neatly into standard event categories, this represents a material operational milestone—the completion and disclosure of a detailed technical and economic assessment of a major mining project that would inform investors' understanding of the project's viability and development status.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-14
Item 8.01
Palmer Square Capital BDC Inc. discloses management's unaudited estimate of net asset value (NAV) per share as of June 30, 2026 ($13.21). For a Business Development Company, NAV is a critical metric for investor valuation and pricing. While this appears to be a routine periodic disclosure, the NAV estimate is material to investors assessing the fund's performance and share value. However, the disclosure does not fit neatly into standard 8-K event categories (not earnings, not a restatement, not a going-concern issue), warranting classification as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-14
Item 2.02
The Board declared a cash distribution of $0.09 per share to stockholders. This routine dividend distribution is material to investors as it affects shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Trinity Capital announced on July 14, 2026, its intention to voluntarily transfer the listings of its common stock and senior notes from Nasdaq to the New York Stock Exchange and NYSE Texas, with trading expected to commence on or about July 27, 2026. This strategic relisting involves changes to ticker symbols and trading venues for both securities.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Apollo-managed funds completed the acquisition of Emerald Holding, Inc. on July 14, 2026, for $5.03 per share in cash, resulting in a change of control and the cessation of Emerald's NYSE trading. The transaction also included the acquisition of Questex, LLC, creating a combined B2B experiential events and media platform, with Emerald becoming a wholly-owned subsidiary and its board members ceasing service.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-14
Item 5.07
This is a classic Item 5.07 disclosure reporting the final certified voting results from Gloo Holdings' 2026 annual meeting of stockholders held on July 13, 2026. The filing presents tabulated results for two proposals: election of three directors (Bishop Claude Alexander, Jr., John Furst, and Derek Green) and ratification of Crowe LLP as independent auditor. The disclosure includes vote counts (For, Against/Withheld, Abstentions, and Broker Non-Votes) certified by the inspector of elections, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Ares Real Estate funds completed an all-cash acquisition of Whitestone REIT for $19.00 per share, valued at approximately $1.7 billion, resulting in a change of control and the company's delisting from NYSE. The transaction included the merger of Whitestone with Merger Sub and the merger of Whitestone's operating partnership with Merger OP, with Whitestone ceasing to exist as a publicly traded entity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Whitestone REIT notified NYSE on July 14, 2026 of the completion of its acquisition by Ares Real Estate funds and requested cessation of trading and delisting via Form 25. Trading was suspended on July 14, 2026, and the company intends to file Form 15 to deregister under Section 12(g).
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-14
Item 5.02
Six board members and officers departed from Whitestone REIT effective as of the Company Merger Effective Time, as a direct consequence of the completion of Ares' acquisition of the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Strategic Storage Trust VI, Inc. entered into a definitive Agreement and Plan of Merger on July 14, 2026, to acquire Strategic Storage Growth Trust III, Inc. in an all-stock transaction. The merger combines two SmartStop-sponsored REITs and includes acquisition of 12 wholly-owned self-storage facilities, 50% equity interests in three unconsolidated real estate ventures, and beneficial interests in three DST-sponsored programs, with a combined company expected to have a total asset value of approximately $1.2 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Research Alliance Corp IV entered into multiple material definitive agreements in connection with its initial public offering, including an Underwriting Agreement, Investment Management Trust Agreement, Registration and Shareholder Rights Agreement, and Private Placement Shares Purchase Agreement. These agreements establish the company's capitalization and governance framework for pursuing a business combination.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 3.02
Research Alliance Corp IV completed an unregistered private placement of 275,000 Class A ordinary shares to the Sponsor at $10.00 per share, generating $2.75 million in proceeds pursuant to Section 4(a)(2) of the Securities Act, simultaneously with the IPO closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-14
Item 5.02
Alan Musso and John Maslowski were appointed to the Board of Directors effective July 10, 2026, in connection with the Company's IPO, with concurrent appointments to the Audit, Nominating, and Compensation committees.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-07-14
Item 8.01
Research Alliance Corp IV announced the pricing and closing of a $75 million initial public offering, establishing the company's public capitalization and status as a special purpose acquisition company (SPAC).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 8.01
Erasca entered into an underwriting agreement on July 13, 2026 to issue and sell 31,428,572 shares of common stock at $17.50 per share, with expected net proceeds of approximately $516.0 million (or $593.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly references the shelf registration statement on Form S-3 and prospectus supplement, confirming this is a registered offering rather than an unregistered private placement, but it remains a material dilutive equity issuance that would significantly affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-14
Item 8.01
The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-14
Item 1.01
Banzai International completed a registered public offering of 327,273 shares of Class A common stock at $2.75 per share on July 14, 2026, generating approximately $0.9 million in gross proceeds, with an additional 45-day overallotment option for 36,364 shares. This registered equity issuance under an effective Form S-3 shelf registration statement dilutes existing shareholders and represents a material capital-raising event.
View raw filing on EDGAR →
8-K
Terminal Other
confidence 95%
filed 2026-07-14
Item 8.01
Churchill Capital Corp IX's board determined on July 14, 2026, that the company is unable to consummate a business combination by the August 6, 2026 deadline and has decided to cease operations, redeem all outstanding public shares at approximately $10.89 per share, liquidate, and delist from Nasdaq. This represents a terminal event materially threatening the registrant's continued existence—the company is winding up and dissolving entirely due to failure to complete its SPAC business combination objective.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-07-14
Item 1.01
Sunbelt Rentals completed the issuance and sale of $1.2 billion in Senior Notes, consisting of $450 million in 4.950% notes due 2030 and $750 million in 5.650% notes due 2036, pursuant to an indenture dated July 14, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-14
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Shareholders held on July 11, 2026. The filing reports the outcomes of three proposals: election of directors (James W. Bernau and Sean M. Cary both elected with >91% support), ratification of Baker Tilly US, LLP as independent auditors (97.78% approval), and advisory approval of executive compensation (82.34% approval). This is a quintessential Item 5.07 disclosure of shareholder voting results at an annual meeting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
The Board appointed two new directors, Christopher Riccardi and Greg Voorhies, effective July 11, 2026, with terms expiring at the 2028 annual meeting. This is a clear director appointment disclosure under Item 5.02, and director appointments are material events affecting the composition and governance of the company's board.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces that Jinxin Technology has regained compliance with Nasdaq's Minimum Bid Price Requirement (Listing Rule 5550(a)(2)) after receiving a deficiency notice on January 29, 2026. The company evidenced a closing bid price at or above US$1.00 for 10 consecutive business days from June 26 to July 10, 2026, thereby curing the deficiency and closing the matter. This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and faced potential delisting within a 180-day cure period, but has now remedied that condition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-14
Item 7.01
ADI Global Distribution is disclosing an investor day event held on July 14, 2026, in connection with its pending spin-off from Resideo Technologies. The filing includes a press release and investor presentation outlining ADI's standalone strategy, financial framework, and medium-term financial targets (4-6% revenue CAGR, >10% Adjusted EBITDA CAGR by 2030, $80M+ in run-rate operating savings). While the spin-off itself is a material M&A activity, this Item 7.01 disclosure focuses on the strategic and operational positioning of ADI as an independent company rather than the separation transaction mechanics, making it primarily an operational/strategic disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-14
EX-99.1
The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for "Treatment of Advanced Metastatic Cancer," which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M&A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces Steakholder Foods' U.S. market entry with its Perfecta™ Premium Plant-Based Meat product line, including the arrival of the first shipment and planned distribution through KeHE Distributors across dozens of retail outlets in the Northeastern USA. This is a material operational and strategic milestone—the company's entry into a major new market with a branded consumer product—but does not fit the specific event categories (M&A, earnings, executive changes, debt, etc.). It represents a significant business development and product commercialization event that would affect a reasonable investor's assessment of the company's growth prospects and market execution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-14
EX-99.1
This press release announces a framework collaboration agreement with a leading global defense system integrator to supply radar systems for three projects, with initial orders already placed and additional orders anticipated in 2026-2027. The disclosure represents a material operational and commercial milestone—entry into a new high-value vertical (defense/homeland security) beyond automotive, with exclusive radar provider status and demonstrated customer commitment through initial deliveries. While not a discrete M&A transaction, it is a significant strategic partnership and customer win that would affect a reasonable investor's assessment of the company's growth prospects and market expansion.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-14
EX-99.3
This is a formal earnings release dated July 14, 2026, announcing Globavend's unaudited financial results for the six months ended March 31, 2026 (first half fiscal 2026). The document discloses revenue of US$14.8 million (8.0% increase), operating loss of US$369,978, net loss of US$30,887, and key operational metrics including 44% increase in average daily shipments. The release is material as it provides investors with periodic financial performance and operational updates essential to assessing the registrant's financial condition and business trajectory.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-14
Item 5.02
The filing discloses the appointment of Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. While the disclosure also includes compensatory arrangements (base salary of $440,000, annual bonus eligibility, and stock option grant of 750,000 shares), the principal action is the appointment of a named executive officer to a C-suite position. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 75%
filed 2026-07-14
Item 8.01
The disclosure describes a €20 million EIB loan that became due June 1, 2026, with the EIB reserving all rights and threatening enforcement action while negotiations continue. This represents a triggering event—a debt obligation in default or at imminent risk of default—that could accelerate financial obligations and materially affect the company's liquidity and financial position. While styled as "ongoing discussions," the EIB's reservation of rights and warning that enforcement is not contemplated only "while discussions remained ongoing" signals a covenant breach or technical default scenario typical of Item 2.04 disclosures.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces termination of a letter of intent for the acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This is a material M&A event — the termination of a proposed transaction. The statement from Chief Strategy Officer Matthew Nicoletti explicitly states "Perpetuals has decided not to further pursue the acquisition" and "the earlier letter of intent has been terminated," which constitutes a material change in the status of a contemplated acquisition that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-14
EX-99.1
This is a press release announcing preliminary unaudited H1 2026 financial highlights, including revenue of approximately $11.4 million (up 115% versus H1 2025), cash position of $495 million, and reaffirmed FY 2026 guidance of 50%–100% revenue growth. The document explicitly states "Preliminary H1 2026 Financial Highlights (Unaudited)" and notes that "WISeKey expects to publish its full H1 2026 consolidated financial results in September 2026." This is a discrete earnings announcement for an interim period, not the periodic financial report itself.
View raw filing on EDGAR →